The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 06, 2016

Filed:

Jul. 11, 2014
Applicant:

Tate & Lyle Ingredients France Sas, Villeneuve d'Ascq., FR;

Inventors:

Thierry Naeye, Touffers, FR;

Alexandra Einerhand, Alkmaar, NL;

Michel Lopez, Nogent sur Seine, FR;

Susan M. Potter, Decatur, IL (US);

Magali Remaud-Siméon, Ramonville, FR;

Pierre Frédéric Emmanuel Monsan, Mondonville, FR;

Assignee:

TATE & LYLE INGREDIENTS FRANCE SAS, Villeneuve D' ASCQ., FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C08B 37/02 (2006.01); A61K 31/721 (2006.01); A23L 1/308 (2006.01); A61K 31/702 (2006.01); A61K 31/733 (2006.01); A61K 35/741 (2015.01); A61K 45/06 (2006.01); C08L 5/02 (2006.01); C12P 19/08 (2006.01); C12P 19/18 (2006.01); C07B 37/00 (2006.01); A23L 1/30 (2006.01); A61K 35/00 (2006.01);
U.S. Cl.
CPC ...
C08B 37/0021 (2013.01); A23L 1/30 (2013.01); A23L 1/308 (2013.01); A61K 31/702 (2013.01); A61K 31/721 (2013.01); A61K 31/733 (2013.01); A61K 35/741 (2013.01); A61K 45/06 (2013.01); C07B 37/00 (2013.01); C08L 5/02 (2013.01); C12P 19/08 (2013.01); C12P 19/18 (2013.01); A23V 2002/00 (2013.01); A61K 2035/115 (2013.01);
Abstract

Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.


Find Patent Forward Citations

Loading…